Patient characteristics
| Patient characteristics . | With new ADs after CBT (n = 52) . | Without new ADs after CBT (n = 726) . | P . | |
|---|---|---|---|---|
| Age at CBT, y (range) | 5 (0.2-45) | 16 (0.11-67) | < .0001 | |
| Male sex, n (%) | 33 (63%) | 408 (56%) | .33 | |
| CMV+ prior to CBT, n (%) | 23 (46%) | 417 (60%) | .05 | |
| Reason for CBT malignant disease, n (%) | Acute leukemia | 16 (31%) | 418 (58%) | Malignant versus nonmalignant disease < .0001 |
| MDS | 4 (8%) | 80 (11%) | ||
| CML | 5 (10%) | 36 (5%) | ||
| Lymphoma | 1 (2%) | 33 (5%) | ||
| Myeloma | 0 | 3 (0.5%) | ||
| Nonmalignant disease, n (%) | Aplastic anemia | 6 (12%) | 55 (8%) | |
| Hemoglobinopathy | 0 | 15 (2%) | ||
| SCID | 6 (12%) | 51 (7%) | ||
| Histiocytosis | 2 (4%) | 13 (2%) | ||
| Metabolic disease | 12 (23%) | 18 (3%) | ||
| Other* | 0 | 3 | ||
| Time from diagnosis to CBT, mo (range) | 8 (2-87) | 12 (0.5-247) | .04 | |
| Graft characteristics, n (%) | Unrelated donor | 50 (96%) | 665 (92%) | .25 |
| HLA match 5/6 and 6/6 | 33 (66%) | 323 (48%) | .02 | |
| More than 1 CB unit transplanted | 8 (15%) | 141 (19%) | .48 | |
| TNC infused × 107/kg (median) | 5.9 (1.4-25) | 3.7 (0.2-31) | .005 | |
| ABO matched | 19 (40%) | 250 (39%) | .91 | |
| ABO minor mismatch | 11 (22%) | 166 (26%) | ||
| ABO major mismatch | 18 (38%) | 233 (36%) | ||
| Conditioning regimen, n (%) | RIC | 9 (18%) | 168 (24%) | .32 |
| TBI | 9 (18%) | 254 (35%) | .01 | |
| ATG/alemtuzumab | 38 (76%) | 527 (78%) | .73 | |
| GVHD prophylaxis, n (%) | CsA + steroids | 26 (52%) | 443 (63%) | .23 |
| CsA + MMF + steroids | 7 (14%) | 162 (23%) | ||
| Patient characteristics . | With new ADs after CBT (n = 52) . | Without new ADs after CBT (n = 726) . | P . | |
|---|---|---|---|---|
| Age at CBT, y (range) | 5 (0.2-45) | 16 (0.11-67) | < .0001 | |
| Male sex, n (%) | 33 (63%) | 408 (56%) | .33 | |
| CMV+ prior to CBT, n (%) | 23 (46%) | 417 (60%) | .05 | |
| Reason for CBT malignant disease, n (%) | Acute leukemia | 16 (31%) | 418 (58%) | Malignant versus nonmalignant disease < .0001 |
| MDS | 4 (8%) | 80 (11%) | ||
| CML | 5 (10%) | 36 (5%) | ||
| Lymphoma | 1 (2%) | 33 (5%) | ||
| Myeloma | 0 | 3 (0.5%) | ||
| Nonmalignant disease, n (%) | Aplastic anemia | 6 (12%) | 55 (8%) | |
| Hemoglobinopathy | 0 | 15 (2%) | ||
| SCID | 6 (12%) | 51 (7%) | ||
| Histiocytosis | 2 (4%) | 13 (2%) | ||
| Metabolic disease | 12 (23%) | 18 (3%) | ||
| Other* | 0 | 3 | ||
| Time from diagnosis to CBT, mo (range) | 8 (2-87) | 12 (0.5-247) | .04 | |
| Graft characteristics, n (%) | Unrelated donor | 50 (96%) | 665 (92%) | .25 |
| HLA match 5/6 and 6/6 | 33 (66%) | 323 (48%) | .02 | |
| More than 1 CB unit transplanted | 8 (15%) | 141 (19%) | .48 | |
| TNC infused × 107/kg (median) | 5.9 (1.4-25) | 3.7 (0.2-31) | .005 | |
| ABO matched | 19 (40%) | 250 (39%) | .91 | |
| ABO minor mismatch | 11 (22%) | 166 (26%) | ||
| ABO major mismatch | 18 (38%) | 233 (36%) | ||
| Conditioning regimen, n (%) | RIC | 9 (18%) | 168 (24%) | .32 |
| TBI | 9 (18%) | 254 (35%) | .01 | |
| ATG/alemtuzumab | 38 (76%) | 527 (78%) | .73 | |
| GVHD prophylaxis, n (%) | CsA + steroids | 26 (52%) | 443 (63%) | .23 |
| CsA + MMF + steroids | 7 (14%) | 162 (23%) | ||
Other includes congenital erythropoietic porphyria, autoimmune hemolytic anemia, and dyserythropoietic anemia.
CMV+ indicates CMV-specific IgG present at CBT; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; TNC, total nucleated cell; RIC, reduced-intensity conditioning; TBI, total body irradiation; ATG, antithymocyte globulin; and MMF, mycophenolate mofetil.